We observed a perfect match (100% specificity and sensitivity of the BEAMing technique compared to Ion Torrent and Cobas FDA-approved tumor mutation assessment kits) in the results of our analysis of KRAS, NRAS, PIK3CA and BRAF mutations in tumor and prior treatment plasma samples. Here, KRAS is linked to neoplasm.